EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

Guest Editorial Commentary on the Findings of the GLAGOV Randomized Clinical Trial

Jakub Podolec, Lukasz Niewiara

US Cardiology Review · 2017

DOI: 10.15420/usc.11.1.ge ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift US Cardiology Review, 2017. Verfasst von Jakub Podolec und 1 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Evolocumab – a human monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9) – significantly reduces low-density lipoprotein cholesterol levels. This agent has been tested in a series of clinical trials, one of which is discussed here: the GLAGOV study. Statintreated patients with coronary disease were treated with evolocumab or placebo with the result that patients in the evolocumab group low-density lipoprotein cholesterol (LDL-C) levels were significantly lower than the placebo group. Athersclerotic plaque regression was noticed in greater number of patients treated with evolocumab compared with placebo (64.3% versus 47.3%). While we await results from large outcome trials on PCSK9 inhibitors, the GLAGOV trial provides interesting findings of clinical advantages that may extend to LDL-C levels as low as 20 mg/dl.

Zitieren

APA

Podolec, J., & Niewiara, L. (2017). Guest Editorial Commentary on the Findings of the GLAGOV Randomized Clinical Trial. US Cardiology Review. https://doi.org/10.15420/usc.11.1.ge

Vancouver

Podolec J, Niewiara L. Guest Editorial Commentary on the Findings of the GLAGOV Randomized Clinical Trial. US Cardiology Review. 2017. doi:10.15420/usc.11.1.ge

BibTeX
@article{Podolec2017,
  author = {Podolec, Jakub and Niewiara, Lukasz},
  title = {Guest Editorial Commentary on the Findings of the GLAGOV Randomized Clinical Trial},
  journal = {US Cardiology Review},
  year = {2017},
  doi = {10.15420/usc.11.1.ge}
}
Kostenlos starten →